Market Research Logo

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2019

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2019

Summary

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 9 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Bladder Cancer, Melanoma, Prostate Cancer, Autoimmune Disorders, Bone Metastasis, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Colon Carcinoma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM) and Relapsed Multiple Myeloma.
The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
  • The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development
Biomics Biotechnologies Co Ltd
Bioneer Corp
Boehringer Ingelheim GmbH
Canget BioTekpharma LLC
IMV Inc
MimiVax LLC
Optimum Therapeutics LLC
Oxford Vacmedix UK Ltd
Polyplus-Transfection SA
Stemline Therapeutics Inc
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles
Antibody to Target Survivin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGA-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1361849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1644 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1740 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPX-Survivac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MV-2C2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OVM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UC-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Autoimmune Diseases, Glioblastoma Multiforme and Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Colon Carcinoma and Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target BIRC5 for Relapsed Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones
Featured News & Press Releases
Jan 29, 2019: IMV announces clinical update for DPX-Survivac program in ovarian cancer following positive feedback from U.S. FDA
Dec 13, 2018: IMV presents updated positive data from phase 1b/2 combination clinical trial in advanced ovarian cancer at 2018 ESMO Immuno-Oncology Congress
Dec 10, 2018: IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac's Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
Nov 28, 2018: Brain Cancer Immunotherapy SurVaxM extends survival, even in hard-to-treat patients
Nov 22, 2018: IMV amends Phase Ib/II trial of recurrent ovarian cancer drug
Nov 16, 2018: Stemline Therapeutics announces oral presentation of SL-701 phase 2 data in second-line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
Oct 16, 2018: Stemline Therapeutics announces SL-701 clinical data to be featured, including an Oral Presentation, at upcoming ESMO 2018 Congress
Sep 18, 2018: IMV announces early positive results from phase 2 clinical trial of lead candidate DPX-Survivac in combination with Merck’s Keytruda in patients with DLBCL
Sep 11, 2018: IMV announces phase 2 basket trial in collaboration with Merck to evaluate DPX-Survivac in combination with KEYTRUDA across five solid tumor indications
Aug 09, 2018: IMV reaches multiple milestones in advanced ovarian cancer clinical trial
Jun 13, 2018: Immunotherapy Vaccine Shows Great Promise in Treating Brain Cancer Patients
Jun 05, 2018: Stemline Therapeutics Announces Positive Data Presentations on SL-701 at ASCO
Jun 03, 2018: IMV Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting
May 29, 2018: Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit
May 21, 2018: MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Biomics Biotechnologies Co Ltd, H1 2019
Pipeline by Bioneer Corp, H1 2019
Pipeline by Boehringer Ingelheim GmbH, H1 2019
Pipeline by Canget BioTekpharma LLC, H1 2019
Pipeline by IMV Inc, H1 2019
Pipeline by MimiVax LLC, H1 2019
Pipeline by Optimum Therapeutics LLC, H1 2019
Pipeline by Oxford Vacmedix UK Ltd, H1 2019
Pipeline by Polyplus-Transfection SA, H1 2019
Pipeline by Stemline Therapeutics Inc, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019
List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook